|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
AU2009204483B2
(en)
|
2008-01-04 |
2014-03-13 |
Intellikine, Llc |
Certain chemical entities, compositions and methods
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
EP2448938B9
(en)
|
2009-06-29 |
2015-06-10 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
EP2552208A4
(en)
*
|
2010-03-31 |
2014-07-09 |
Glaxo Group Ltd |
IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
|
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
|
JP5937102B2
(ja)
*
|
2010-12-14 |
2016-06-22 |
エレクトロフォレティクス リミテッド |
カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
|
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
KR20180080358A
(ko)
|
2011-01-10 |
2018-07-11 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀린온 및 이의 고체 형태의 제조 방법
|
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
KR102030609B1
(ko)
|
2011-09-02 |
2019-10-11 |
인사이트 홀딩스 코포레이션 |
Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
|
|
HUE043171T2
(hu)
|
2011-10-07 |
2019-08-28 |
Takeda Pharmaceuticals Co |
Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
|
|
KR101987514B1
(ko)
|
2011-10-18 |
2019-06-10 |
아스텔라스세이야쿠 가부시키가이샤 |
이환식 헤테로환 화합물
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
EP2785692B1
(en)
|
2011-12-01 |
2017-09-27 |
ChemoCentryx, Inc. |
Substituted anilines as ccr(4) antagonists
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
HRP20161774T1
(hr)
|
2012-06-13 |
2017-02-24 |
F. Hoffmann - La Roche Ag |
Novi diazaspirocikloalkan i azaspirocikloalkan
|
|
US9611267B2
(en)
|
2012-06-13 |
2017-04-04 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as FGFR inhibitors
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
US9630976B2
(en)
|
2012-07-03 |
2017-04-25 |
Ono Pharmaceutical Co., Ltd. |
Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
|
|
WO2014009891A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Piramal Enterprises Limited |
Heterocyclic compounds for use in the treatment of cancers
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
CN113679717A
(zh)
|
2012-08-22 |
2021-11-23 |
康奈尔大学 |
用于抑制肌成束蛋白的方法
|
|
KR102046499B1
(ko)
*
|
2012-08-24 |
2019-11-19 |
트레벤티스 코포레이션 |
벤조푸라잔 항아밀로이드 화합물 및 방법
|
|
CN102850341B
(zh)
*
|
2012-09-05 |
2015-02-18 |
浙江工业大学 |
一种噻二唑类化合物及其制备与应用
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
BR112015004111A2
(pt)
|
2012-09-25 |
2017-07-04 |
Hoffmann La Roche |
novos derivados bicíclicos
|
|
CN103739594A
(zh)
*
|
2012-10-17 |
2014-04-23 |
南京大学 |
一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
|
|
IL291945B2
(en)
|
2012-11-01 |
2025-11-01 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CA2888338C
(en)
|
2012-11-27 |
2021-07-20 |
Thomas Helledays Stiftelse For Medicinsk Forskning |
Mth1 inhibitors for treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
WO2014103801A1
(ja)
*
|
2012-12-28 |
2014-07-03 |
株式会社新日本科学 |
イミダゾピリジン誘導体を有効成分として含むｏｃｔ３活性阻害剤又はｏｃｔ３検出剤
|
|
WO2014124458A1
(en)
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
AR095079A1
(es)
|
2013-03-12 |
2015-09-16 |
Hoffmann La Roche |
Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
|
|
WO2014144747A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
HK1220325A1
(zh)
|
2013-03-15 |
2017-05-05 |
Whitehead Institute For Biomedical Research |
苯并咪唑衍生物及其用途
|
|
US9045477B2
(en)
*
|
2013-03-15 |
2015-06-02 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
TWI649318B
(zh)
|
2013-04-19 |
2019-02-01 |
英塞特控股公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
US9797882B2
(en)
|
2013-07-09 |
2017-10-24 |
The Translational Genomics Research Institute |
Method of screening for a compound for inhibitory activity of FN14-tweak interaction
|
|
US9238034B2
(en)
*
|
2013-07-09 |
2016-01-19 |
The Translational Genomics Research Institute |
FN14 antagonists and therapeutic uses thereof
|
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
|
GB201314452D0
(en)
|
2013-08-13 |
2013-09-25 |
Ostara Biomedical Ltd |
Embryo implantation
|
|
RU2570907C2
(ru)
*
|
2013-10-21 |
2015-12-20 |
Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" |
Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
|
|
KR102254957B1
(ko)
|
2013-11-22 |
2021-05-25 |
씨엘 바이오사이언시즈 엘엘씨 |
골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)
|
|
KR20160087900A
(ko)
|
2013-11-26 |
2016-07-22 |
에프. 호프만-라 로슈 아게 |
신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
|
|
GB201321738D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
WO2015106025A1
(en)
|
2014-01-09 |
2015-07-16 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Substituted benzoxazine and related compounds
|
|
US10087186B2
(en)
|
2014-01-29 |
2018-10-02 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds as LRRK2 kinase inhibitors
|
|
ES2717757T3
(es)
|
2014-01-29 |
2019-06-25 |
Glaxosmithkline Ip Dev Ltd |
Compuestos
|
|
US10167286B2
(en)
|
2014-02-11 |
2019-01-01 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
WO2015123437A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
PE20161573A1
(es)
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
US9493450B2
(en)
|
2014-02-13 |
2016-11-15 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
CA2940144C
(en)
|
2014-02-20 |
2023-06-13 |
Cornell University |
Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
|
|
HUE044999T2
(hu)
*
|
2014-02-27 |
2019-12-30 |
Treventis Corp |
Benzofurazán tartalmú anti-amiloid vegyületek
|
|
KR20160128428A
(ko)
|
2014-03-26 |
2016-11-07 |
에프. 호프만-라 로슈 아게 |
오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
|
|
SI3122750T1
(sl)
|
2014-03-26 |
2019-12-31 |
F. Hoffmann-La Roche Ag |
Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
|
|
WO2015157382A1
(en)
*
|
2014-04-11 |
2015-10-15 |
Emory University |
Treatment of neurodegenerative diseases with asparagine endopeptidase (aep) inhibitors and compositions related thereto
|
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9840482B2
(en)
*
|
2014-04-19 |
2017-12-12 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
|
HUE057317T2
(hu)
*
|
2014-04-23 |
2022-04-28 |
Dart Neuroscience Llc |
Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
|
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
CN104059060B
(zh)
*
|
2014-05-30 |
2017-08-01 |
西安交通大学 |
一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
|
|
EP3152195A4
(en)
|
2014-06-04 |
2017-12-13 |
Thomas Helledays Stiftelse För Medicinsk Forskning |
Mth1 inhibitors for treatment of cancer
|
|
RU2016151390A
(ru)
|
2014-06-04 |
2018-07-17 |
Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг |
Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний
|
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
CA2954681A1
(en)
|
2014-07-31 |
2016-02-04 |
Merck Patent Gmbh |
Indolizine derivatives and their use in neurodegenerative diseases
|
|
EP3189070A4
(en)
|
2014-08-04 |
2018-06-27 |
Drexel University |
Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
GB201419579D0
(en)
*
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
TWI568737B
(zh)
|
2014-11-05 |
2017-02-01 |
達特神經科學（開曼）有限責任公司 |
作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
|
|
JP6708130B2
(ja)
|
2014-12-25 |
2020-06-10 |
小野薬品工業株式会社 |
キノリン誘導体
|
|
GB201501302D0
(en)
|
2015-01-27 |
2015-03-11 |
Ostara Biomedical Ltd |
Embryo implantation
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
DK3831833T3
(da)
|
2015-02-27 |
2022-11-14 |
Incyte Holdings Corp |
Fremgangsmåder til fremstillingen af en pi3k-inhibitor
|
|
EP4591936A3
(en)
|
2015-03-23 |
2025-10-15 |
Tianli Biotech Pty Ltd |
Treatment of respiratory diseases
|
|
PE20180455A1
(es)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de lsd1
|
|
MA41898A
(fr)
|
2015-04-10 |
2018-02-13 |
Hoffmann La Roche |
Dérivés de quinazolinone bicyclique
|
|
EP3288933B1
(en)
*
|
2015-04-30 |
2021-10-06 |
Musc Foundation for Research Development |
Oxindole compounds and pharmaceutical compositions thereof
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
|
GB201508276D0
(en)
|
2015-05-14 |
2015-06-24 |
Electrophoretics Ltd |
A casein kinase 1 delta inhibitor
|
|
GB201509134D0
(en)
|
2015-05-28 |
2015-07-15 |
Electrophoretics Ltd |
Biomolecules involved in Alzheimer's disease
|
|
JP6707630B2
(ja)
*
|
2015-06-01 |
2020-06-10 |
バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ |
置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
|
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
WO2016202756A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
US10167270B2
(en)
*
|
2015-07-01 |
2019-01-01 |
Northwestern University |
Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
|
|
WO2017000277A1
(en)
|
2015-07-01 |
2017-01-05 |
Merck Sharp & Dohme Corp. |
Substituted triazolo bicycliccompounds as pde2 inhibitors
|
|
SG10202001219UA
(en)
|
2015-08-12 |
2020-03-30 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
CN105061462B
(zh)
*
|
2015-08-18 |
2017-05-24 |
沈阳药科大学 |
含有酰胺的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
|
|
JP6886967B2
(ja)
*
|
2015-09-04 |
2021-06-16 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
フェノキシメチル誘導体
|
|
TWI730002B
(zh)
|
2015-09-18 |
2021-06-11 |
日商科研製藥股份有限公司 |
聯芳系化合物及含有此化合物之醫藥
|
|
RU2018112230A
(ru)
|
2015-09-24 |
2019-10-30 |
Ф. Хоффманн-Ля Рош Аг |
Бициклические соединения в качестве ингибиторов atx
|
|
CN107635995B
(zh)
|
2015-09-24 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
作为atx抑制剂的二环化合物
|
|
JP6877413B2
(ja)
|
2015-09-24 |
2021-05-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
|
|
AU2016328365B2
(en)
|
2015-09-24 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
New bicyclic compounds as dual ATX/CA inhibitors
|
|
WO2017062500A2
(en)
*
|
2015-10-05 |
2017-04-13 |
The Trustees Of Columbia University In The City Of New York |
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
|
GB201517523D0
(en)
|
2015-10-05 |
2015-11-18 |
Ostara Biomedical Ltd |
Methods and compositions for managing reproduction
|
|
WO2017063966A1
(en)
|
2015-10-13 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
|
|
ES2765738T3
(es)
|
2015-11-02 |
2020-06-10 |
Janssen Pharmaceutica Nv |
Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
|
|
US10450274B2
(en)
*
|
2015-12-07 |
2019-10-22 |
Hinova Pharmaceuticals Inc. |
Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug
|
|
US20200375996A1
(en)
*
|
2015-12-15 |
2020-12-03 |
D.E. Shaw Research, Llc |
Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
|
|
CN107033087B
(zh)
*
|
2016-02-04 |
2020-09-04 |
西华大学 |
1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
|
|
WO2017133258A1
(zh)
*
|
2016-02-04 |
2017-08-10 |
西华大学 |
1h-吲唑类衍生物及其作为ido抑制剂的用途
|
|
CN107840826B
(zh)
*
|
2016-09-19 |
2021-07-09 |
西华大学 |
1h-吲唑类衍生物及其作为ido抑制剂的用途
|
|
CN109414410B
(zh)
|
2016-04-22 |
2022-08-12 |
因赛特公司 |
Lsd1抑制剂的制剂
|
|
AU2017275657B2
(en)
|
2016-06-02 |
2021-08-19 |
Novartis Ag |
Potassium channel modulators
|
|
EA202092442A3
(ru)
|
2016-06-07 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
BR112019000589A2
(pt)
|
2016-07-14 |
2019-04-24 |
Pfizer Inc. |
pirimidina carboxamidas como inibidores da enzima vanina-1
|
|
WO2018030762A1
(ko)
*
|
2016-08-09 |
2018-02-15 |
세종대학교산학협력단 |
Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물
|
|
JP7471818B2
(ja)
|
2016-08-18 |
2024-04-22 |
ヴィダック ファーマ リミテッド |
ピペラジン誘導体、医薬組成物、及びその使用方法
|
|
MY199759A
(en)
|
2016-09-02 |
2023-11-21 |
Tisento Therapeutics Inc |
Fused bicyclic sgc stimulators
|
|
CN106432235B
(zh)
*
|
2016-10-19 |
2018-02-02 |
南通大学 |
靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途
|
|
MA46589A
(fr)
|
2016-10-24 |
2019-08-28 |
Yumanity Therapeutics Inc |
Composés et utilisations de ces derniers
|
|
EP3535269B1
(en)
|
2016-11-02 |
2020-12-09 |
Janssen Pharmaceutica NV |
[1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
|
|
UA125302C2
(uk)
*
|
2016-11-02 |
2022-02-16 |
Янссен Фармацевтика Нв |
Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
|
|
KR20190067788A
(ko)
*
|
2016-11-02 |
2019-06-17 |
얀센 파마슈티카 엔.브이. |
Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
|
|
US11008325B2
(en)
|
2016-11-14 |
2021-05-18 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
|
EP3541378A4
(en)
*
|
2016-11-16 |
2020-10-07 |
University of South Florida |
ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE MITIGATION OF PROTEINOPATHIES
|
|
EP3566055B1
(en)
|
2017-01-06 |
2025-03-12 |
Janssen Pharmaceutica NV |
Scd inhibitor for the treatment of neurological disorders
|
|
KR102446529B1
(ko)
*
|
2017-01-10 |
2022-09-23 |
에테하 취리히 |
세포 보호 화합물 및 이의 용도
|
|
CN106831573B
(zh)
*
|
2017-01-23 |
2019-05-24 |
南阳师范学院 |
(n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
|
|
UA123810C2
(uk)
|
2017-01-23 |
2021-06-02 |
Цадент Терапеутікс, Інк. |
Модулятори калієвих каналів
|
|
CN106748969B
(zh)
*
|
2017-01-23 |
2019-06-18 |
南阳师范学院 |
一种n-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途
|
|
CN119707932A
(zh)
|
2017-01-26 |
2025-03-28 |
小野药品工业株式会社 |
喹啉衍生物的乙磺酸盐
|
|
NZ755447A
(en)
|
2017-02-01 |
2023-05-26 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
|
|
CN106943397B
(zh)
*
|
2017-03-01 |
2020-08-04 |
浙江大学 |
雄激素受体拮抗剂及其应用
|
|
EP3596059B1
(en)
|
2017-03-16 |
2024-04-24 |
F. Hoffmann-La Roche AG |
Heterocyclic compounds useful as dual atx/ca inhibitors
|
|
WO2018167113A1
(en)
|
2017-03-16 |
2018-09-20 |
F. Hoffmann-La Roche Ag |
New bicyclic compounds as atx inhibitors
|
|
PT3448859T
(pt)
|
2017-03-20 |
2019-10-25 |
Forma Therapeutics Inc |
Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
|
|
AU2018239542C1
(en)
|
2017-03-23 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as SHP2 inhibitors
|
|
MX388196B
(es)
|
2017-04-26 |
2025-03-19 |
Basilea Pharm Int Ag |
Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
|
|
EP3634406B1
(en)
*
|
2017-05-12 |
2023-09-06 |
Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville |
3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JOP20190282A1
(ar)
|
2017-06-09 |
2019-12-05 |
Novartis Ag |
مركبات وتركيبات لحث تكوّن الغضاريف
|
|
CN110997664A
(zh)
*
|
2017-06-14 |
2020-04-10 |
欧洲分子生物学实验室 |
用于疗法的苯并呋喃酰胺及其杂芳族类似物
|
|
KR20200019228A
(ko)
|
2017-06-21 |
2020-02-21 |
미토키닌, 인크. |
신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
|
|
GB201710851D0
(en)
*
|
2017-07-06 |
2017-08-23 |
Galápagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
|
|
WO2019014100A1
(en)
|
2017-07-10 |
2019-01-17 |
Celgene Corporation |
ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
|
|
CA3069720A1
(en)
|
2017-07-11 |
2019-01-17 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
CN111094264A
(zh)
*
|
2017-09-11 |
2020-05-01 |
保土谷化学工业株式会社 |
具有嘧啶环结构的化合物及有机电致发光元件
|
|
TWI846350B
(zh)
|
2017-09-15 |
2024-06-21 |
美商佛瑪治療公司 |
作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
|
|
JP7223998B2
(ja)
|
2017-10-13 |
2023-02-17 |
小野薬品工業株式会社 |
Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
|
|
CA3079081A1
(en)
|
2017-10-19 |
2019-04-25 |
Michael D. Bartberger |
Benzimidazole derivatives and their uses
|
|
CA3083000A1
(en)
|
2017-10-24 |
2019-05-02 |
Yumanity Therapeutics, Inc. |
Compounds and uses thereof
|
|
WO2019123375A1
(en)
*
|
2017-12-21 |
2019-06-27 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
|
|
JP2021507945A
(ja)
*
|
2017-12-21 |
2021-02-25 |
グリアファーム エスエー |
認知症を含む神経障害のための組成物および治療方法
|
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
WO2019173437A1
(en)
*
|
2018-03-06 |
2019-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Positive allosteric modulators of dopamine 1 receptor and method of use thereof
|
|
EP3543231A1
(en)
*
|
2018-03-19 |
2019-09-25 |
ETH Zurich |
Compounds for treating cns- and neurodegenerative diseases
|
|
ES3043183T3
(en)
|
2018-03-23 |
2025-11-25 |
Janssen Pharmaceutica Nv |
Compounds and uses thereof
|
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
|
ES2991427T3
(es)
|
2018-05-04 |
2024-12-03 |
Incyte Corp |
Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
|
|
TWI815887B
(zh)
*
|
2018-05-15 |
2023-09-21 |
美商愛彼特生物製藥股份有限公司 |
經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
CN119258070A
(zh)
|
2018-06-01 |
2025-01-07 |
因赛特公司 |
治疗pi3k相关病症的给药方案
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
MX2023013508A
(es)
|
2018-06-29 |
2023-12-13 |
Forma Therapeutics Inc |
Inhibicion de la proteina de union a creb (cbp).
|
|
CN113166153B
(zh)
|
2018-07-05 |
2024-11-01 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
BR112021002165A2
(pt)
*
|
2018-08-06 |
2021-05-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação
|
|
KR102817790B1
(ko)
|
2018-08-29 |
2025-06-05 |
케모센트릭스, 인크. |
C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
US11278527B2
(en)
|
2018-09-04 |
2022-03-22 |
Brown University |
Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder
|
|
CN113301900B
(zh)
*
|
2018-09-09 |
2024-11-29 |
夸纳特制药股份公司 |
酪蛋白激酶1抑制剂在治疗血管疾病中的应用
|
|
CN112996795B
(zh)
|
2018-09-18 |
2024-11-12 |
尼坎治疗公司 |
作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
|
|
US12053458B2
(en)
|
2018-09-19 |
2024-08-06 |
Novo Nordisk Health Care Ag |
Treating sickle cell disease with a pyruvate kinase R activating compound
|
|
ES2989438T3
(es)
|
2018-09-19 |
2024-11-26 |
Novo Nordisk Healthcare Ag |
Activación de la piruvato cinasa R
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|
|
MX2021004647A
(es)
|
2018-10-22 |
2021-08-16 |
Novartis Ag |
Formas cristalinas de moduladores de los canales de potasio.
|
|
CN112912139B
(zh)
*
|
2018-10-23 |
2024-07-09 |
第一三共株式会社 |
联芳基衍生物
|
|
WO2020093098A1
(en)
|
2018-11-07 |
2020-05-14 |
The University Of Melbourne |
Novel compounds for the treatment of respiratory diseases
|
|
CN109503563B
(zh)
*
|
2018-12-10 |
2020-05-12 |
济南大学 |
多功能乙酰胆碱酯酶抑制剂及其应用
|
|
KR102128509B1
(ko)
*
|
2018-12-19 |
2020-07-01 |
한국과학기술연구원 |
말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
|
|
EP3906229A4
(en)
*
|
2019-01-04 |
2022-11-16 |
Bellbrook Labs, Llc |
INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENT
|
|
WO2020146612A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Esters and carbamates as modulators of sodium channels
|
|
US12441703B2
(en)
|
2019-01-10 |
2025-10-14 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
MX2021008903A
(es)
|
2019-01-24 |
2021-11-04 |
Yumanity Therapeutics Inc |
Compuestos y usos de los mismos.
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US12351577B2
(en)
|
2019-03-15 |
2025-07-08 |
Forma Therapeutics, Inc. |
Inhibiting cyclic AMP-responsive element-binding protein (CREB)
|
|
US11505548B2
(en)
|
2019-04-26 |
2022-11-22 |
Celgene Corporation |
Heterocyclic compounds and their use for treatment of helminthic infections and diseases
|
|
UY38687A
(es)
|
2019-05-17 |
2023-05-15 |
Novartis Ag |
Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
|
|
LT4299135T
(lt)
|
2019-06-18 |
2025-09-10 |
Pfizer Inc. |
Benzizoksazolo sulfonamido dariniai
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN119431323A
(zh)
|
2019-07-31 |
2025-02-14 |
贝林格尔·英格海姆国际有限公司 |
作为cd38抑制剂的杂双环酰胺
|
|
RU2746423C2
(ru)
*
|
2019-09-02 |
2021-04-13 |
Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") |
Ингибитор вируса гепатита В (ВГВ)
|
|
CN114615977B
(zh)
|
2019-09-19 |
2025-01-14 |
诺沃挪第克健康护理股份公司 |
丙酮酸激酶r(pkr)活化组合物
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EA202192047A1
(ru)
|
2019-11-13 |
2021-12-08 |
Юманити Терапьютикс, Инк. |
Соединения и их применение
|
|
US12343335B2
(en)
|
2019-11-14 |
2025-07-01 |
Zincure Corp. |
Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
DK4069691T3
(da)
|
2019-12-06 |
2024-10-28 |
Vertex Pharma |
Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AR122711A1
(es)
*
|
2020-06-25 |
2022-09-28 |
Alchemedicine Inc |
COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
|
|
CA3191164A1
(en)
*
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
AU2021345564A1
(en)
*
|
2020-09-17 |
2023-06-01 |
Janssen Pharmaceutica Nv |
Casein kinase 1 delta modulators
|
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
|
GB202101734D0
(en)
*
|
2021-02-08 |
2021-03-24 |
Cerevance Inc |
Novel Compounds
|
|
TW202246232A
(zh)
|
2021-02-19 |
2022-12-01 |
英商蘇多生物科學有限公司 |
Ｔｙｋ２抑制劑及其用途
|
|
TW202246233A
(zh)
|
2021-02-19 |
2022-12-01 |
英商蘇多生物科學有限公司 |
Tyk2抑制劑及其用途
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
WO2022222963A1
(zh)
*
|
2021-04-21 |
2022-10-27 |
长春金赛药业有限责任公司 |
含咪唑稠环类衍生物、其制备方法及其在医药上的应用
|
|
MA64853B1
(fr)
|
2021-06-04 |
2025-11-28 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
AU2022364646B2
(en)
*
|
2021-10-15 |
2025-10-09 |
Lomond Therapeutics, Inc. |
SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
|
|
JP2025513455A
(ja)
|
2022-04-22 |
2025-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛の治療のためのヘテロアリール化合物
|
|
CN115466211B
(zh)
*
|
2022-06-09 |
2024-02-23 |
中国人民解放军空军军医大学 |
一种n-苯基喹啉-4-胺类化合物及其应用
|
|
US20250388584A1
(en)
*
|
2022-07-14 |
2025-12-25 |
Shanghai Raising Pharmaceutical Co., Ltd. |
Tpk agonist and method for treating neurodegenerative diseases using same
|
|
UY40374A
(es)
|
2022-08-03 |
2024-02-15 |
Novartis Ag |
Inhibidores de inflamasoma nlrp3
|
|
WO2024083150A1
(zh)
*
|
2022-10-19 |
2024-04-25 |
长春金赛药业有限责任公司 |
一种nk3r拮抗剂的晶型及其制备方法和应用
|
|
CN120917015A
(zh)
*
|
2023-01-20 |
2025-11-07 |
元启(苏州)生物制药有限公司 |
Srpk1抑制剂和使用方法
|
|
WO2024159285A1
(pt)
*
|
2023-01-30 |
2024-08-08 |
Eurofarma Laboratórios S.A. |
Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
|
|
PY2404641A
(es)
*
|
2023-01-30 |
2024-10-03 |
Eurofarma Laboratorios S A |
COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS
|
|
IT202400002560A1
(it)
*
|
2024-02-07 |
2025-08-07 |
Univ Pisa |
Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare
|
|
CN118666857B
(zh)
*
|
2024-06-26 |
2025-02-25 |
江西农业大学 |
一种喹啉类化合物及其在农用杀菌剂中的应用
|
|
CN119060061B
(zh)
*
|
2024-08-26 |
2025-09-16 |
浙江师范大学 |
一类苯并嘧啶硫醚类化合物作为sting蛋白小分子抑制剂的应用
|